GSGayathri Sridhar

Gayathri Sridhar

*This is an algorithmically generated author record based on publicly available information.

Gayathri Sridhar has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Hector S. Izurieta

    B Center for Biologics Evaluation and Research , U.S. Food and Drug Administration , Silver Spring , MD , USA

    4 shared publications
  • Basil Golding

    Center for Biologics Evaluation and Research US Food and Drug Administration Rockville Maryland

    3 shared publications
  • Mikhail Menis

    Center for Biologics Evaluation and Research US Food and Drug Administration Rockville Maryland

    3 shared publications
  • Mikhail V. Ovanesov

    Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA

    3 shared publications
  • Nandini Selvam

    A HealthCore Inc. , Alexandria , VA , USA

    3 shared publications
  • Steven A. Anderson

    Center for Biologics Evaluation and Research US Food and Drug Administration Rockville Maryland

    3 shared publications

Latest Publications

  • Open Access

    Evaluation of optic neuritis following human papillomavirus vaccination

    by Gayathri Sridhar, Fang Tian, Richard Forshee, Martin Kulldorff, Nandini Selvam, Andrea Sutherland, Wilson Bryan, Samuel Barone, Lei Xu, Hector S. Izurieta

    To assess the relationship between human papillomavirus (HPV) vaccination and occurrence of optic neuritis (ON) and to evaluate a claims-based algorithm for identification of ON. Females of 9–26 year olds in the HealthCore's Integrated Research Database (HIRDSM) with and without claims evidence of HPV vaccination between 2007 and 2012 were included in this study. Potential ON cases were identified using the claims-based algorithm, positive predictive value (PPV) was determined using medical chart review. For the claims analysis, two study designs, a self-controlled temporal scan statistic and a retrospective matched cohort analysis, were used. ON was defined based on an algorithm developed using diagnosis and procedure codes from the medical claims. The PPV for ON cases using charts that had enough information for reviewers to make a determination was 62.5% (95% CI: 49.5%–74.3%). With the self-controlled temporal scan statistic, the primary analysis restricting on recommended vaccination schedule timing showed an increased risk of potential ON after second dose (RR = 3.39; p = 0.03), this finding was not confirmed for any of the additional analyses performed for individual or combined doses. With the cohort design, there was no increased risk of potential ON following vaccination in either individual or combined dose analyses. The risk of potential ON was higher among participants with a history of prior autoimmune diseases. In conclusion, identifying confirmed ON cases through administrative claims data proved challenging. The claims-based analysis in this study did not provide evidence for an association of ON with HPV vaccination.


  • Immune globulins and same‐day thrombotic events as recorded in a large health care database during 2008 to 2012

    by Gayathri Sridhar, Bola F. Ekezue, Hector S. Izurieta, Nandini Selvam, Mikhail V. Ovanesov, Hozefa A. Divan, Yideng Liang, Basil Golding, Richard A. Forshee, Steven A. Anderson, et al.

    Background: Thrombotic events (TEs) are rare and serious adverse events after administration of immune globulin (IG) products. Our study evaluated the occurrence of same‐day TEs for different IG products and ascertained potential risk factors.Study Design and Methods: This retrospective cohort study utilized HealthCore's Integrated Research Database (HIRD) to assess individuals exposed to IGs during 2008 to 2012. IG products were identified using recorded procedure codes and TEs were ascertained using ICD‐9‐CM diagnosis codes. The unadjusted same‐day TE rates (per 1000 persons exposed) were estimated overall and by IG products, age, and sex. Multivariable logistic regression analyses were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for same‐day TEs by IG products.Results: Of 14,944 individuals exposed to IG products, 233 (15.6 per 1000 persons) had TE diagnosis code(s) recorded on the same‐day as the IG exposure. Compared to Gammagard Liquid, Gammaplex (OR, 20.96; 95% CI, 2.45‐179.33) and Vivaglobin (OR, 2.74; 95% CI, 1.19‐6.32) users had a significantly increased same‐day TE risk. Elevated, but nonsignificant TE risks were identified for Octagam, Gamunex, Privigen, and Lyophilized IG(s). An increased TE risk was also found with older age (≥45 years), prior TEs, and other health conditions.Conclusion: Our claims‐based cohort study suggests a potentially elevated TE risk with different IG products and shows importance of recipient factors such as older age, previous TE, hypercoagulable state(s), and other health conditions. The results of this study suggest the need for continuous evaluation of procoagulant activity and manufacturing processes for IG products to further assure their safety.


  • Open Access

    Hyperimmune globulins and same‐day thrombotic adverse events as recorded in a large healthcare database during 2008–2011

    by Mikhail Menis, Gayathri Sridhar, Nandini Selvam, Mikhail V. Ovanesov, Hozefa A. Divan, Yideng Liang, Dorothy Scott, Basil Golding, Richard Forshee, Robert Ball, et al.

    Thrombotic events (TEs) are rare serious complications following administration of hyperimmune globulin (HIG) products. Our retrospective claims‐based study assessed occurrence of same‐day TEs following administration of HIGs during 2008–2011 and examined potential risk factors using HealthCore's Integrated Research Database (HIRDSM) and laboratory testing of products' procoagulant Factor XIa activity by U.S. Food and Drug Administration. Multivariable regression was used to estimate same‐day TE risk for different products. Of 101,956 individuals exposed to 23 different HIG product groups, 86 (0.84 per 1,000 persons) had a TE diagnosis code (DC) recorded on the same day as HIG administration. Unadjusted same‐day TE DC rates (per 1,000 persons) ranged from 0.4 to 148.9 for different products. GamaSTAN S/D IG >10 cc had statistically significantly higher same‐day TE DC risk compared to Tetanus IG (OR = 57.57; 95% CI = 19.72–168.10). Increased TE risk was also observed with older age (≥45 years), prior thrombotic events, and hypercoagulable state(s). Laboratory investigation identified elevated Factor XIa activity for GamaSTAN S/D, HepaGam B, HyperHep B S/D, WinRho SDF, HyperRHO S/D full dose, and HyperTET S/D. Our study, for the first time, identified increase in the same‐day TE DC risk with GamaSTAN S/D IG >10 cc and suggests potentially elevated TE risk with other HIGs. Am. J. Hematol. 88:1035–1040, 2013.


  • Immune globulins and thrombotic adverse events as recorded in a large administrative database in 2008 through 2010

    by Gregory W. Daniel, Mikhail Menis, Gayathri Sridhar, Dorothy Scott, Anna E. Wallace, Mikhail V. Ovanesov, Basil Golding, Steven A. Anderson, Jay Epstein, David Martin, et al.

    BACKGROUND: Thrombotic events (TEs) are rare but often serious adverse events that could occur after administration of immune globulin (IG) products. Our study objective was to assess occurrence of recorded TEs after administration of different US‐licensed IG products and investigate potential risk factors using a large administrative database.STUDY DESIGN AND METHODS: This is a retrospective claims‐based cohort study of individuals exposed to IG products from January 1, 2008, through September 30, 2010, using HealthCore's Integrated Research Database, a longitudinal health care database. IG products were identified by recorded Healthcare Common Procedure Coding System codes. TEs were ascertained via International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis codes. Logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for same‐day TEs by IG product, while controlling for confounders.RESULTS: Of 11,785 individuals exposed to IG products in the study period, 122 (1%) had TE(s) recorded on the same day as IG administration. TE rates per 1000 persons exposed ranged from 6.1 to 20.5 for different IG product groups. Vivaglobin users had an increased same‐day TE risk compared to reference Gammagard Liquid users (OR, 3.56; 95% CI, 1.54‐8.23). An increased TE risk was also found with older age (≥45 years), prior TE(s), and hypercoagulable state(s).CONCLUSION: The study suggests potentially elevated TE rates for different IG products, including subcutaneous. It also identifies important recipient TE risk factors and suggests that risk–benefit profiles should be weighed before IG administration. The observed differences may be due to various factors such as dosage, administration rates, and product manufacturing processes that warrant further evaluation.